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1. Introduction
DNA sequences, both Watson–Crick and mismatched base 
pairs, can be recognized with a variety of compounds that 
bind in the DNA minor groove (Neidle 2001; Lacy et al 
2003; Tidwell et al 2003; Wilson et al 2005; Pindur et al 
2005). These compounds can be broadly classifi ed as those 
that bind without a signifi cant increase in the groove width 
of the free DNA, and those that bind with a broadening 
of the groove. The former class is exemplifi ed by ligands 
containing aromatic rings and charged end-groups while the 
latter is typifi ed by selective polyamide hairpin and related 
compounds such as distamycin and netropsin (Dervan and 
Edelson 2003). The forces that dominate small molecule 
minor groove-binding interactions are electrostatic, van 
der Waals, hydrophobic and hydrogen bonding. A crucial 
requirement for the ligand is a crescent shape that is 
complementary to the curvature of the minor groove. 
Various aspects of minor groove drug–DNA recognition 
are revealed with the help of deposited X-ray structures in 
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the protein databank (PDB) and the nucleic acid databank 
(NDB) (Berman et al 2000). Experimental, comparative 
structural and molecular modelling studies suggest that 
sequence specifi city is often linked to key hydrogen bonds 
between the base pairs and the small molecule (Kennard 
1993; Tabernero et al 1996; Dervan 2001; Morávek et al 
2002; Rohs et al 2005). 
The importance of weak C−H···O hydrogen bonds 
in macromolecules is a well-established phenomenon 
(Desiraju and Steiner 1999). We have earlier described 
their signifi cance, as supporting interactions of stronger 
N−H···O and O−H···O bonds in protein–ligand complexa-
tion (Sarkhel and Desiraju 2004; Panigrahi and Desiraju 
2007). Based on the assumption that strong hydrogen 
bonding in drug–receptor interactions are thus inherently 
assisted by weak hydrogen bonds (Aparna et al 2005), 
the aim of the present study is to analyse the importance 
of strong and weak hydrogen bonds in drug–DNA 
complexes. 
1.1 Nomenclature
At this stage, and to avoid any possible linguistic 
misunderstanding, it is necessary to defi ne the terms ‘strong’ 
and ‘weak’, as used in this paper, and by us elsewhere 
(Desiraju and Steiner 1999. The weak hydrogen bond is 
defi ned as an interaction X–H···A wherein a hydrogen 
atom forms a bond between two structural moieties X and 
A, of which one or even both are only of moderate to low 
electronegativity. There is no energetic implication in the 
defi nition of these terms ‘strong’ and ‘weak’. Hydrogen 
bonds cover a wide and continuous energy scale from 
around –0.5 to nearly –40 kcal/mol. The very weakest of 
hydrogen bonds (in energy terms) are barely distinguishable 
from van der Waals interactions while the strongest ones 
(in energy terms) are stronger than weak covalent bonds. 
Any energy cut-off between strong and weak bonds 
is arbitrary and therefore disputable. In principle, one 
could categorize hydrogen bonds as ‘weak’ and ‘strong’ 
according to an energetic criterion (an energy cut-off 
value), phenomenological criteria (distances or infrared] 
wave number shifts), or operational criteria (what they 
can do). The results of such alternative classifi cations are 
not necessarily consistent, because there are always cases 
where a hydrogen bond is, say ‘strong’ in terms of energy 
and ‘weak’ in terms of geometry, or the other way round. To 
avoid all confusion, therefore, we use a somewhat subjective, 
but undeniably unambiguous, defi nition. Hydrogen bonds 
formed by good donors (O–H, N–H) and good acceptors (N, 
O, halide) are labelled ‘strong’. Accordingly O–H···O, N–
H···O, O–H···N and N–H···N hydrogen bonds will be termed 
‘strong’ whatever be their energy stabilization, geometrical 
parameters or furcation status. Conversely, if either a poor 
donor (C–H, S–H) or a poor acceptor is involved ( -cloud, 
multiple bonds) (Nishio et al 1998), or both the donor and 
acceptor are poor (C–H… ), the hydrogen bond is termed 
‘weak’. There is substantial overlap between this defi nition 
and an energy-based defi nition but also some areas of 
difference. Notably, we do not consider as ‘weak’ very 
minor components of N–H···O bifurcated arrangements, 
which are frequently seen in biomolecules. Also, strongly 
bent O–H···O and N–H···O hydrogen bonds, which occur 
in sterically adverse situations, are not considered ‘weak’ 
by us. 
Different terminologies have been employed by others. 
Jeffrey and Saenger (1991) have classifi ed hydrogen 
bonds as ‘strong’ and ‘weak’ while Jeffrey (1997) has 
elaborated this further to ‘strong’, ‘moderate’ and ‘weak’. 
The reader will note that there is a near correspondence 
between the category we term ‘strong’ and Jeffrey calls 
‘moderate’. Jeffrey’s terminology is in keeping with the 
biological literature where bonds such as O–H···O–H, and 
especially O
w
–H···O
w
–H, are not taken to be particularly 
‘strong’, and N–H···O defi nitely veer towards what is 
understood as ‘weak’. Our bias in these defi nitions is of 
chemical origin. The reason we refer to Jeffrey’s middle 
category as ‘strong’ originates from supramolecular 
chemistry considerations. By ‘strong’ we mean hydrogen 
bonds that are able to control crystal and supramolecular 
structure effectively. This certainly includes O–H···O=C, 
N–H···O=C and O–H···O–H. By ‘weak’ we mean hydrogen 
bonds whose infl uence on crystal structure and packing 
is variable. In the end, though, all these discussions on 
nomenclature are semantic in nature. All kinds of hydrogen 
bonds are different and likewise, all kinds of weak hydrogen 
bonds are also different. Our defi nitions of ‘strong’ and 
‘weak’ hydrogen bonds are certainly subject to debate and 
discussion, but they offer the advantages of consistency 
and lack of ambiguity. For a further classifi cation of 
weak hydrogen bonds, the reader is advised to consult the 
book written by Desiraju and Steiner (1999).
1.2 Aims of this work
The fi rst section of the present study deals with a 
comparative analysis of strong and weak hydrogen bonds in 
a database of 70 drug–DNA complex crystal structures. The 
second part deals with the molecular modelling applications 
of these results in a particular system. For the latter exercise, 
we have chosen a set of 26 amidinium derivatives targeted 
against Human African Trypanosomes (Athri et al 2006), 
Trypanosoma brucei rhodesiense (TBR) and Trypanosoma 
brucei gambiense (TBG). These organisms are responsible 
for Human African Trypanosomiasis (HAT) or sleeping 
sickness. The drugs currently used for the treatment of HAT 
are either toxic or diffi cult to use (Seed and Boykin 2001). 
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Only one drug for treating HAT is currently undergoing 
clinical trials (Boykin 2002; Wilson et al 2005). The orally 
available prodrug DB289 is converted systemically into 
another diamidine (DB75) that is active against the early-
stage disease.
2. Materials and methods
2.1 Drug–DNA complexes from PDB
A set of 70 unique minor groove drug–DNA complexes 
was obtained from the PDB (table 1). The drug molecules 
present in these cases are berenil (3 complexes), furans and 
thiophenes (8), pentamidines (5), netropsin (12), distamycin 
(5), Hoechst drugs (16), benzimidazoles (14), DAPI (2), 
polyamide (3), pyridines (2). The therapeutic uses of the 
above-mentioned drugs are listed in table 2. H-atoms were 
added to the drug–DNA complexes, and then subjected 
to minimization keeping the heavy atoms rigid. This was 
carried out in MOE with the MMFFx force fi eld (Halgren 
1996; MOE 2006). The MOE optimized geometries 
were analysed with our in-house hydrogen bond analysis 
program, HBAT.
2.2 Hydrogen bond analysis tool 
Strong and weak hydrogen bonds were analysed with an 
in-house developed program, HBAT (Tiwari et al 2006). 
Hydrogen bond analysis tool (HBAT) analyses and tabulates 
all hydrogen bonds present in a PDB fi le. The output 
fi le provides distance-angle distributions across various 
geometry ranges while tabulation of frequencies for each 
residue, ligand, water and nucleic acids is done easily 
for any kind of interaction. It is a user-friendly desktop 
tool, which operates both with default and user-selected 
parameters. The standard H-bonding criteria were set as d 
(H···A)  2.8 Å and  (X−H···A)  90°. These liberal cut-offs 
were used, and this is common in statistical studies, because 
it is preferable to have some false-positives rather than a 
situation where genuine interactions get eliminated because 
of over-stringent cut-off limits.
2.3  Docking of HAT inhibitors
Molecule building, geometry optimizations and minimiza-
tions were carried out using the MMFFx force fi eld in 
the MOE software. Docking was carried out with GOLD 3.0 
(Cambridge Crystallographic Data Centre, Cambridge CB2 
1EZ, UK). The amidinium inhibitors (26 compounds, table 3) 
were selected from the literature (Athri et al 2006). Of 
these, seven (furan-based compounds) are present in 
the database of 70 experimental crystal structures analysed 
in the fi rst section of this paper. Docking was performed 
for each of these 26 inhibitors into the DNA in eight 
experimental crystal structures; in other words, a total of 
208 docking experiments were performed. Seven of these 
structures correspond to the seven furans mentioned above; 
the eighth corresponds to a thiophene-based inhibitor in 
structure ID-1VZK (Scheme I), which has been shown to be 
a good choice for docking for minor groove binders (Evans 
and Neidle 2006). This eighth structure is also contained 
in the earlier database of 70 structures. Signifi cantly, 
the correlations observed for the docking geometries 
obtained from this eighth (thiophene-based) structure 
were signifi cantly better than the others, and accordingly 
only results from this set of 26 docking experiments are 
discussed further. A region of 7.0  radius around the ligand 
was defi ned as the active site for each drug–DNA complex. 
Default-set parameters were used in the docking. For each 
of the 10 independent Genetic Algorithm (GA) runs, with 
a selection pressure 1.1, 100,000 GA operations were 
performed on a set of 5 islands. The population size of 200 
individuals was specifi ed. Default operator weights of 95, 
95 and 10, respectively, were used for crossover, mutation 
and migration. To further speed up the calculation, the GA 
docking was stopped when the top three solutions were 
within 1.5 Å root mean square deviation (RMSD) of each 
other. The interaction analysis was carried out with HBAT 
as described above. 
3. Results and discussion
3.1 Overview of strong and weak hydrogen bonds in 
drug–DNA complexes
DNA contains a variety of strong and weak hydrogen bond 
functional groups (Scheme II). These groups are evenly 
exposed in the minor and major grooves. The ratio of the 
number of exposed donors to acceptors for AT and GC pairs 
in the major groove is 1:2, while it is 1:2 for GC and 0:2 
for AT in the minor groove. The possible acceptors present 
in the major groove are [A{N(7)}], [G{N(7)}], [G{N(6)}] 
Scheme 1
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Table 1. Minor groove drug–DNA complexes in this study: (a) berenil 1–3, (b) furans 4–11,  (c) pentamidines 12–16, (d) netropsin 
17–28, (e) distamycin 29–33, (f) Hoechst drugs 34–49,  (g) benzimidazoles 50–63, (h) DAPI 64–65, (i) polyamides 66–68, (j) pyridines 
69–70
Sl No. PDB ID NDB ID Resolution Pubmed ID Hetero group
1 1D63 GDL016 2 1640462 BRN
2 2DBE GDL009 2.5 2323343 BRN
3 268D GDLB42 2 n/a BRN
4 289D GDL045 2.2 8917643 D19
5 1VZK - 1.7 n/a D1B
6 1EEL  - 2.4 11128631 D24
7 1FMQ DD0034 2 11128631 D34
8 1FMS DD0035 1.9 11128631 D35
9 360D GDL056 1.8 9611230 BPF
10 227D GDL036 2.2 8639524 BGF
11 298D GDL044 2.2 8917643 D18
12 1M6F DD0052 1.7 12431090 CGQ
13 166D GDL027 2.2 7813486 PET
14 1D64 GDL015 2.1 1643044 PNT
15 102D GDL032 2.2 7608897 TNT
16 1PRP GDL023 2.1 8268158 TNT
17 101D GDLB31 2.2 7711020 NT
18 121D GDL014 2.2 8395202 NT
19 195D GDL030 2.3 n/a NT
20 1D85 GDLB17 2.5 1332773 NT
21 1D86 GDL018 2.2 1332773 NT
22 1DNE GDL004 2.4 2539859 NT
23 1DVL DD0024 2.4 11914483 NT
24 261D GDJ046 2.4 9125500 NT
25 358D GDJB55 2.5 9826773 NT
26 375D GDJ059 2.4 9826773 NT
27 474D GDJB58 2.4 9826773 NT
28 6BNA GDLB05 2.2 2991536 NT
29 267D GDLB41 2 n/a DMY
30 1JTL DD0042 1.9 12071949 DMY
31 1K2Z DD0046 2.4 12071949 DMY
32 2DND GDL003 2.2 3479798 DMY
33 378D GDH060 2.4 10089456 DMY
34 127D GDL022 2 1371249 HT
35 128D GDLB19 2.5 1371249 HT
36 129D GDL021 2.2 1371249 HT
37 130D GDLB20 2.5 1371249 HT
38 1D43 GDL010 2 1718416 HT
39 1D44 GDL011 2 1718416 HT
40 1D45 GDL012 1.9 1718416 HT
41 1D46 GDL013 2 1718416 HT
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Table 1 (Continued)
Sl No. PDB ID NDB ID Resolution Pubmed ID Hetero group
42 1DNH GDL002 2.2 2452403 HT
43 264D GDL026 2.4 7517864 HT
44 296D GDL028 2.2 7515488 HT
45 8BNA GDL006 2.2 2445998 HT
46 311D GDL052 2.2 9162901 HT2
47 303D GDL048 2.2 9017011 RO2
48 302D GDL047 2.2 9017011 RO2
49 447D DD0007 2.2 10666470 BBZ
50 263D GDL039 2.2 8901516 TBZ
51 459D DD0014 2.3 10373586 TBZ
52 1FTD  - 2 11170623 E97
53 403D BDD001 1.4 9692982 HT1
54 443D DD0004 1.6 10666470 IA
55 445D DD0006 2.6 10666470 IA
56 449D DD0009 2.1 10666470 IA
57 442D DD0003 1.6 10666470 IB
58 444D DD0005 2.4 10666470 IB
59 448D DD0008 2.2 10666470 IB
60 109D GDL033 2 n/a IBB
61 1LEX GDL037 2.2 8527438 IPL
62 1LEY GDL038 2.2 8527438 IPL
63 269D GDLB43 2.1 n/a HT
64 1D30 GDL008 2.4 2627296 DAP
65 432D DD0002 1.9 10600105 DAP
66 1CVX DD0020 2.2 10623546 HP2
67 1CVY DD0021 2.1 10623546 IPY
68 408D BDD003 2.1 9756473 IPY
69 144D GDLB24 2.2 8373768 SN6
70 328D GDL053 2.6 9321660 SN7
Table 2. Minor groove binders (MGB) and their respective therapeutic uses
Sl. No. Drug Therapeutic uses
1 Berenil Antiprotozoal agents, intercalating agents trypanocidal agents
2 Furans Antitrypanosomal, Pneumocystis carinii
3 Pentamidines African trypanosomiasis and leishmaniasis, AIDS-related P. carinii pneumonia
4 Netropsin Filaricides, antiviral agents, anticancer agents
5 Distamycin Anticancer and antiviral agents
6 Hoechst drugs Filaricides and antifungal agent
7 Benzimidazoles Antiviral agents
8 DAPI Trypanocidal agents
9 Polyamide Anticancer agents
10 Pyridines Anticancer agents
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Sl. No. Code Structure PIC
50
IC
50
 (in µM)
1 DB690
++
HH O
NH2
N
H
NH2
N
H
8.79 0.0016
2 DB867
++
HH
ONH2
N
H
N
NH2
N
H
8.69 0.0020
3 DB351
++
HH
SNH2
N
H
NH2
N
H
8.51 0.00302
4 DB994
++
HH
O
N
NH2
N
H
N
NH2
N
H
8.39 0.0040
5 DB820
++
HH
ONH2
N
H
N
NH2
N
H
8.31 0.0048
6 DB75 ONH2
N
H
NH2
N
H
HH
++
8.29 0.0051
7 1RJL164
++
HH N O
NH2
N
H
NH2
N
H
8.28 0.0052
8 DB417
++
ONH2
N
H
NH2
N
H
8.18 0.0066
9 DB484
++
HH
O
N
NH2
N
H
NH2
N
H
8.15 0.0070
10 DB427
++
ONH2
N
H
NH2
N
H
8 0.0100
11 DB313
++
ONH2
N
H
NH2
N
H
7.97 0.0107
12 DB518
++
O
NH2
N
H
NH2
N
H
7.86 0.0138
13 DB262
++
HH
N
HNH2
N
H
NH2
N
H
7.85 0.0141
14 DB829
++
HH
O
N
NH2
N
H
N
NH2
N
H
7.77 0.0169
15 DB481
++
O
NH2
N
H
NH2
N
H
7.72 0.0190
16 DB193 ONH2
N
H
NH2
N
H
++
7.63 0.0234
17 DB312
++
ONH2
N
H
NH2
N
H
7.63 0.0234
18 DB235 ONH2
N
H
NH2
N
H
++
7.45 0.0354
19 DB244
++
ONH2
N
H
NH2
N
H
7.45 0.0354
Table 3. Amidinium-based HAT inhibitors used in docking and their activities.
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while donors belong to the amino groups in the [A{N(6)}] 
and [C{N(4)}] positions. In the minor groove, the acceptors 
are [A{N(3)}], [G{N(3)}], [T{O(2)}], [C{O(2)}] and the 
donor is the amino group of [G{N(2)}]. Several proteins 
of functional importance bind to the major groove, whereas 
non-covalently binding drugs bind to the minor groove. 
As discussed earlier, the MGB selectively bind to the 
AT-rich region. Therefore, acceptors present in the minor 
groove, notably N(3) of purine and C(2)=O of pyrimidine, 
are important sites for drug–DNA interaction. Apart from 
nucleotides, phosphate groups and the ribose O-atoms are 
also acceptors. 
3.2 Hydrogen bond analysis
Both strong and weak hydrogen bonds are observed in the 
minor groove of drug–DNA complexes. As expected, N(3) 
of purine and O(2) of pyrimidine are important (table 4). 
The exceptions are polyamides and DAPI drugs, which 
20 DB480
++
O
NH2
N
H
NH2
N
H
7.41 0.0389
21 DB240 7.35 0.0446ONH2
N
H
NH2
N
H
++
22 DB249
++
ONH2
N
H
NH2
N
H
7.17 0.0676
23 DB181 ONH2
N
H
NH2
N
H
++
7.16 0.0691
24 DB422
++
ONH2
N
H
NH2
N
H NH2NH2
7.01 0.0977
25 DB421
++
ONH2
N
H
NH2
N
H NO2O2N
6.99 0.1023
26 DB568
++
ONH2
N
H
NH2
N
H
O O
6.77 0.1698
Scheme 1I
Sunil K Panigrahi and Gautam R Desiraju8
J. Biosci. 32(4), June 2007
interact with adenine N(3), guanine N(3), thymine O(2) and 
cytosine O(2). A schematic diagram for a typical inhibitor 
for each class is shown in fi gure 1. The types of strong 
and weak hydrogen bonds observed in the case of purine 
are N−H···N(3) and C−H···N(3), and for pyrimidine they 
are N−H···O(2) and C−H···O(2). Also observed clearly are 
N−H···Ow and C−H···Ow interactions between the drug and 
water. The distribution of types of strong and weak hydrogen 
bonds in a total of 835 interactions are: (a) purine C−H···N(3) 
18%, N−H···N(3) 12%, (b) pyrimidine C−H···O(2) 18%, 
N−H···O(2) 18%, (c) C−H···Ow 21%, N−H···Ow 12% 
(fi gure 2a). The total number of C−H···N and C−H···O 
hydrogen bonds taken together is 481, while for N−H···N 
and N−H···O the total is 354. The present dataset contains 
70 drug molecules. Thus, on average, each drug molecule 
interacts with DNA through seven weak interactions and fi ve 
strong interactions in the minor groove, which is effectively 
1.4 weak hydrogen bonds for each strong hydrogen bond. 
Apart from nucleotides, drug molecules also interact with 
the sugar moiety, but they rarely interact with the phosphate 
group. The number of interactions observed between drug 
molecules and the deoxyribose sugar and phosphates taken 
together are 118. Among these interactions, deoxyribose 
sugar O4’ of adenine and thymine have more hydrogen 
bonds (fi gure 2b). 
3.3 Donor furcation
The specifi city and affi nity of minor groove-binding 
agents are sensitive to the local width of the groove. In 
AT-rich sequences, the minor groove is unusually narrow 
(0.3–0.4 nm). Due to the narrow width, a donor present 
Figure 1. Schematic representation of minor groove binders in the minor groove. Strong hydrogen bonds are shown with green arrows, 
exposed ligand atoms in blue contours, and the nearest nucleotides as circles: (a) pentamidine, (b) benzimidazoles, (c) berenil, (d) 
distamycin, (e) furan, (f) Hoechst drugs, (g) netropsin, (h) DAPI, (i) polyamide, (j) pyridine. 
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in a drug molecule possibly is hydrogen bonded to more 
than one acceptor on the wall of the groove. This type of 
situation, where a donor can interact with several acceptors 
simultaneously or an acceptor can interact simultaneously 
with many donors, is termed furcation. The most frequently 
observed furcated interactions in this study involve 
bifurcated and trifurcated donors. Figure 3 shows examples 
of bi- and trifurcated donors in the DB244–DNA complex 
in PDB ID 1EEL. Typically, a single donor from the ligand 
is shared by two or three acceptors of the minor groove. 
Table 5 shows a distribution of strong and weak hydrogen 
bonds at various levels of furcation. With an increase in 
furcation level, the numbers of weak hydrogen bonds 
increase. The numbers of donor-furcated cases are: (a) 
bifurcated, 205; (b) trifurcated, 41; (c) tetrafurcated, 7; (d) 
pentafurcated, 2. 
3.4 Hydrogen bond geometry
For strong hydrogen bonds of the type N−H···N and 
N−H···O, the median H···N/H···O distances, d, are less 
than 2.4 Å and 2.2 Å, respectively (fi gure 4). The cone-
corrected angular distributions for N−H···N and N−H···O 
are similar with maxima in the range of 170–175o. The 
inverse length–angle correlations are also well-behaved 
in these cases. Strong N−H···N and N−H···O hydrogen 
bonds show better linearity compared with weak C−H···N 
and C−H···O hydrogen bonds. The weak C−H···N, C−H···O 
hydrogen bonds have variable geometry. The cone-corrected 
angular distributions of C−H···N and C−H···O interactions 
have maxima at 165–170º and 150–155º, respectively. To 
summarize, the geometries for strong and weak hydrogen 
bonds observed in the drug–DNA complexes are consistent 
and fall within acceptable limits. 
3.5 Human African Trypanosomiasis (docking)
Molecular docking is a very useful technique in rational 
drug design. However, the purpose of using docking in the 
present context is different. Molecular docking was carried 
out to estimate the best drug–DNA geometries in cases where 
the crystal structures of the complex are unknown, assuming 
that strong and weak hydrogen bonds are optimized. 
Accordingly, we selected the best geometry (poses) for 
such complexes to obtain virtual crystal geometries for the 
26 selected HAT inhibitors. The inhibitors were docked 
separately to each of the 8 drug–DNA complexes of the 
amidinium category. Each docking run was evaluated 
through regression analysis of experimental activities versus 
docking scores. The best correlation r = 0.83 was obtained 
in the case of PDB ID 1VZK, where molecules with 
higher activity show greater docking scores (fi gure 5), 
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showing that our assumption regarding optimization of 
hydrogen bonds is a valid one. The best poses for the 
inhibitors were exported to HBAT for hydrogen bond 
analysis. The docking solutions of molecule DB690 and 
DB568 are shown in fi gure 6. 
Molecule DB690 interacts with DNA through six weak 
and fi ve strong hydrogen bonds. At one end, one amide 
group of the drug molecule is hydrogen-bonded to T(O2). 
Further, this amide is also hydrogen-bonded to a water 
molecule. The water molecule is again hydrogen-bonded to 
the phosphate group present at the opposite strand. The other 
amide group is hydrogen-bonded to C(O2). Between these 
two ends, the weak C−H···N and C−H···O hydrogen bonds 
are present (fi gure 6a). The inactive molecule, DB568 binds 
to DNA with six weak and four strong interactions (fi gure 
6b). The interactions observed between molecule DB690, 
DB568 and DNA are listed in table 6. 
Figure 2. Distribution of hydrogen bonds in drug–DNA 
complexes. Interactions of drug with (a) nucleotides and water, (b) 
sugar and phosphate.
Table 5. Strong and weak hydrogen bonds at various levels of 
donor furcation.
Furcation level C−H···N N−H···N C−H···O N−H···O
Bifurcated 84 69 216 141
Trifurcated 20 20 52 31
Tetrafurcated 6 5 10 7
Pentafurcated 6 - 4 -
Figure 3. Bifurcated and trifurcated hydrogen bonds in DB244–
DNA complex, PDB ID 1EEL. 
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Figure 4. Hydrogen bond geometry for purine (a)–(f) and pyrimidine (g)–(l) acceptors.  In each case, the inverse length–angle scatterplot 
is followed by histograms of distances and cone-corrected angular distributions. 
(a) C–H···N 
(d) N–H···N 
(c) C–H···N (b) N–H···N
(e) C–H···N (f) N–H···N
(g) C–H···O (h) N–H···O (i) C–H···O
(j) N–H···O (k) C–H···O (l) N–H···O
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Figure 5. Fitness scores versus biological activities of HAT inhibitors.
Figure 6. Best docking solutions of (a) molecule DB690 and (b) molecule DB568 in the minor grove. 
(a) (b)
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3.6 Hydrogen bonds in HAT inhibitors
The hydrogen bond geometry for C−H···O(2) and 
N−H···O(2) pyrimidine acceptors are discussed here 
as representatives of strong and weak hydrogen bonds. 
Figure 7 shows the C−H···O and N−H···O hydrogen 
bond geometries which involve DNA pyrimidine for the 
26 selected HAT inhibitors. For N−H···O and C−H···O 
hydrogen bonds, the median H···O distances d are less 
than 2.1 Å and 2.8 Å, respectively. This is normal. The 
inverse length–angle correlations are also consistent for 
both types of hydrogen bonds. The cone-corrected angular 
distribution for N−H···O has a maximum at 175–180º. 
For C−H···O interactions, the maximum lies at 140–145º. 
This too is as expected. Similarly, the hydrogen bond 
geometries obtained for both X-ray structures and the virtual 
complexes are consistent. Docking has produced a set of 
reasonable drug–DNA recognition geometries in the 19 
cases where no crystal structure is available (virtual crystal 
structures).
Table 6a. Hydrogen bonds in the molecule DB690–DNA complex
Type Acceptor Acceptor atom Residue number d (H···A)  D (X···A) q (X−H···A)
C−H···N A N3 6 2.303 3.382 171.8
C−H···N A N3 18 2.602 3.378 127.5
C−H···O T O2 19 2.718 3.28 111.9
C−H···O T O2 19 2.449 3.284 132.4
C−H···O T O2 20 2.693 3.098 101.4
C−H···O T O2 8 2.43 3.053 114.8
N−H···O C O2 9 2.117 3.097 162.7
N−H···O HOH O 24 2.155 2.994 139.1
N−H···O HOH O 24 2.056 2.925 142.6
N−H···O HOH O 25 1.51 2.163 116.7
N−H···O T O2 20 2.135 3.085 155.7
Table 6b. Hydrogen bonds in the molecule DB568–DNA complex
Type Acceptor Acceptor atom Residue number d (H···A)  D (X···A) q (X−H···A)
C−H···N A N3 18 2.775 3.654 137.5
C−H···O A O1P 18 2.767 3.299 109.4
C−H···O A O4’ 18 2.694 3.071 99.67
C−H···O HOH O 25 2.076 3.122 158.1
C−H···O T O1P 8 2.599 3.222 115.1
C−H···O T O2 19 2.683 3.241 111.2
N−H···N G N2 16 2.667 3.146 108.8
N−H···O C O2 9 1.709 2.592 143.4
N−H···O HOH O 25 1.82 2.807 163.5
N−H···O T O4’ 7 2.403 2.836 104.6
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